In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper statements by a competitor. CRA’s causality analysis included consideration of other economic factors that affected product sales, including assessment of market preparation, launch, commercialization, and promotional efforts used to support the product that was allegedly affected by improper marketing support.
CRA adds Kevin Williams, Yale School of Management Professor, as academic affiliate to Antitrust Practice
“I am pleased to welcome Kevin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Kevin is a recognized expert in...